Back
Full-text
Journal article

Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.

  • Lamoth F Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA Clinical Microbiology Laboratory, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland Institute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland.
  • Alexander BD Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA Clinical Microbiology Laboratory, Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA alexa011@mc.duke.edu.
  • 2015-04-22
Published in:
  • Antimicrobial agents and chemotherapy. - 2015
Amphotericin B
Antifungal Agents
Drug Resistance, Fungal
Echinocandins
Fungi
Glucosyltransferases
Glycosides
Humans
Microbial Sensitivity Tests
Mycoses
Retrospective Studies
Triterpenes
English The limited armamentarium of active and oral antifungal drugs against emerging non-Aspergillus molds is of particular concern. Current antifungal agents and the new orally available beta-1,3-d-glucan synthase inhibitor SCY-078 were tested in vitro against 135 clinical non-Aspergillus mold isolates. Akin to echinocandins, SCY-078 showed no or poor activity against Mucoromycotina and Fusarium spp. However, SCY-078 was highly active against Paecilomyces variotii and was the only compound displaying some activity against notoriously panresistant Scedosporium prolificans.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/295841
Statistics
Document views: 18 File downloads:
  • fulltext.pdf: 0